"So I take it that the BTD is not for the 3point MACE with CHF in lieu of Stroke?"

From the news release (my bolding added):

"Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) is pleased to announce the U.S. Food & Drug Administration (“FDA”) has granted Breakthrough Therapy Designation for apabetalone in combination with top standard of care, including high-intensity statins, for the secondary prevention of major adverse cardiac events in patients with type 2 diabetes mellitus and recent acute coronary syndrome."

That statement is broad enough to cover all bases of the different combinations of MACE events presented in BETonMACE, including combinations w/ and w/o stroke or CHF. Keep in mind that further clinical development is likely prior to drug approval. Therefore, the endpoints of future trial(s) will be informed by the observations of BETonMACE.

BDAZ